The first experience of performing combined positron-emission with computed tomography with prostate-specific membrane antigen labeled with gallium-68 in patients with minimal level of prostate-specific antigen after radical prostatectomy
| Autor: | Marina Tlostanova, Andrey Stanzhevskiy, Mariya Ignatova |
|---|---|
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.diagnostic_test business.industry Prostatectomy medicine.medical_treatment Urology chemistry.chemical_element Computed tomography urologic and male genital diseases Prostate-specific antigen Oncology chemistry Glutamate carboxypeptidase II Medicine In patient Gallium business |
| Zdroj: | Scopus-Elsevier |
| Popis: | To assess diagnostic capabilities of new receptor-specific radiopharmaceutical - prostate-specific membrane antigen labeled with gallium-68 (68Ga-PSMA) 66 patients with prostate cancer (PC) after radical prostatectomy underwent combined positron emission with computed tomography (PET/CT). In 61/66 cases PSA level was 0,2-1,0 ng/ml, in 5/66 it did not exceed 0,2 ng/ml. The processing of the results concluded in a visual analysis of the images. In 45/66 patients with PET foci of hyperfaxation of radiopharmaceutical were detected. At the same time structural changes in CT were determined only in 34/45 patients. PSMA-positive cases, not accompanied by radiographic findings, were attributed to false positive results. Indicators of PET/CT information without taking into account X-ray parameters of PSMA-positive changes had a greater diagnostic significance of the method in this category of patients. PET/CT with 68Ga-PSMA is a promising method for diagnosing biochemical recurrence of PC at low PSA values. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|